RxDoctor Payments Data

Tina Eckhardt, MD

Ophthalmology · Bettendorf, IANPI 1952373383

Payments from drug & device makers

$511in general payments, 2019–2025

Across 16 payments — averaging $31.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$167
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$99
  • Tarsus Pharmaceuticals, Inc.$98
  • Oyster Point Pharma, Inc.$43
  • Bausch & Lomb Americas Inc.$39
  • Puma Biotechnology, Inc.$30
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$49397%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$511 in reported general payments places this provider in the 40th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$189,970
Medicare patients
1,282
Services billed
2,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine345$458,237
LumiganBimatoprost145$74,276
XiidraLifitegrast51$58,377
Cyclosporine51$21,089
CombiganBrimonidine Tartrate/Timolol44$20,833
VyzultaLatanoprostene Bunod22$7,427
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol45$4,978
Latanoprost466$4,256
Travoprost22$3,699
Loteprednol Etabonate21$2,694
Brinzolamide11$1,065
Doxycycline Hyclate20$1,020
Timolol Maleate46$877
Fluorometholone11$811
Prednisolone Acetate17$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$21$553,346534 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$39$65,80473 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$99$2,69421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Bettendorf

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →